There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sierra Oncology (SRRA – Research Report), G1 Therapeutics (GTHX – Research Report) and Rubius Therapeutics (RUBY – Research Report) with bullish sentiments.
Sierra Oncology (SRRA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sierra Oncology, with a price target of $35.00. The company’s shares closed last Thursday at $22.29, close to its 52-week high of $24.00.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Sierra Oncology has an analyst consensus of Strong Buy, with a price target consensus of $39.67.
See Insiders’ Hot Stocks on TipRanks >>
G1 Therapeutics (GTHX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics, with a price target of $71.00. The company’s shares closed last Thursday at $10.16, close to its 52-week low of $9.75.
According to TipRanks.com, White is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for G1 Therapeutics with a $38.83 average price target, a 261.2% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $44.00 price target.
Rubius Therapeutics (RUBY)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Rubius Therapeutics today and set a price target of $40.00. The company’s shares closed last Thursday at $12.60.
According to TipRanks.com, Fein is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Rubius Therapeutics with a $20.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRRA:
- What Do Ambarella’s Newly Added Risk Factors Reveal?
- CEO of GM’s Cruise Leaves; Shares Fall 2.8%
- Analysts Offer Insights on Conglomerates Companies: FedEx (FDX) and Siemens Gamesa Renewable Energy, S.A. (OtherGCTAF)
- Avid Bioservices Updates 1 Key Risk Factor
- William Blair Maintains Their Buy Rating on Veeva Systems (VEEV)